Business Wire

March of Dimes and Ferring Announce New Prematurity Research Center at Imperial College London

Jaa

March of Dimes and Ferring Pharmaceuticals today announced that March of Dimes has selected Imperial College London as the first European partner to join its network of Prematurity Research Centers working to find the unknown causes of preterm birth and new ways to prevent it.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180306006632/en/

This March of Dimes Prematurity Research Center at Imperial College London is supported by a grant from Ferring Pharmaceuticals. Both Ferring and March of Dimes are committed to advancing research to help prevent the 15 million preterm births each year worldwide. Preterm birth is responsible for 1.1 million infant deaths each year.1

“We’re delighted that the talented scientists at Imperial College London will join as the sixth March of Dimes Prematurity Research Center to help us get closer to a world in which all babies are born healthy,” said Stacey D. Stewart, president of March of Dimes. “It’s vital that our team is able to share information and findings with colleagues outside of the U.S., in order to accelerate the discovery of solutions to the serious problem of premature birth.”

Globally, too many babies are being born too soon, and too many families are suffering the consequences,” said Per Falk, Executive Vice President and Chief Science Officer, Ferring Pharmaceuticals. “Ferring is committed to addressing unmet patient needs in reproductive medicine and women’s health, including the growing rates of preterm birth worldwide. We believe that this new center will accelerate the development of new healthcare solutions that are urgently needed to help babies that are born earlier than expected.

Phillip Bennett, Professor of Obstetrics and Gynaecology at Imperial College London, and the principal investigator of the new Center, said, “We are proud to have been selected to join the March of Dimes Prematurity Research Center family. Imperial College London and its partner hospitals have renowned clinics for supporting women who deliver preterm, as well as a long tradition of ground-breaking research in this area. As London is a truly global city, we are also fortunate to encompass a large and diverse patient population.”

Our teams of world-class scientists will be using the latest technologies, some unique to Imperial, to study how the body recognises and interacts with bacteria and other microbes in the birth canal. This will enable us to develop methods for predicting--and ultimately preventing--preterm birth.”

The March of Dimes European Prematurity Research Center at Imperial College London will be a partnership between the College and three major London hospitals: Queen Charlotte’s and Chelsea, St. Mary’s Hospital, and Chelsea and Westminster. Each of these hospitals deliver around 5,000 babies a year.

The network of March of Dimes Prematurity Research Centers encompasses approximately 200 scientists in numerous fields, including obstetrics, neonatology, genetics and genomics, immunology, engineering, informatics, and social sciences. (NOTE: See below for a complete list of the Prematurity Research Centers).

Each March of Dimes Prematurity Research Center is assigned a theme or research target. The theme selected for Imperial College London is entitled, “Microbe-Host Interactions.” This team of scientists will identify and characterise these complex processes in order to obtain insight into why some women are at higher risk for preterm birth.

About Preterm Birth
Preterm birth (before 37 weeks of pregnancy) and its consequences are the leading cause of death among children under age five worldwide. Babies who survive an early birth often face lifelong health challenges, such as breathing problems, cerebral palsy, and learning disabilities. The preterm birth rate is on the rise in the United States, climbing for a second year in a row in 2016.

Quick viewable link for B-roll footage on preterm birth: https://www.youtube.com/watch?v=FbFhPnJy3B0

To download B-roll footage on preterm birth: http://bit.ly/2GUyWMsMOD-Imperial-broll

About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalised healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com and @Ferring, or connect with us on Facebook, Instagram and LinkedIn.

About Imperial College London
Imperial College London is one of the world's leading universities. The College's 17,000 students and 8,000 staff are expanding the frontiers of knowledge in science, medicine, engineering and business, and translating their discoveries into benefits for our society.

Imperial is the UK's most international university, according to Times Higher Education, with academic ties to more than 150 countries. Reuters named the College as the UK's most innovative university because of its exceptional entrepreneurial culture and ties to industry.

About March of Dimes
March of Dimes leads the fight for the health of all moms and babies. We support research, lead programs and provide education and advocacy so that every family can have the best possible start. Building on a successful 80-year legacy of impact and innovation, we stand up for every mom and every baby. Visit marchofdimes.org or nacersano.org for more information. Visit shareyourstory.org for comfort and support. Find us on Facebook and follow us on Instagram and Twitter.

Because premature birth is such a complex problem, with multiple causes, March of Dimes has chosen Prematurity Research Centers and partners who can use different tools and methods to examine the factors involved in different ways. Each center’s work informs and amplifies the work the other centers are pursuing.

The other five March of Dimes Prematurity Research Centers are located at (with date of launch):

• Stanford University School of Medicine (2011);

• Ohio Collaborative (2013);

• Washington University in St. Louis (2014);

• University of Pennsylvania Perelman School of Medicine (2014);

• University of Chicago-Northwestern University-Duke University (2015).

# # #

References
1 Born Too Soon: The Global Action Report on Preterm Birth. (WHO, March of Dimes) 2012.

Contact information

For more information, please contact:
Ferring Pharmaceuticals
Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com
Bhavin Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)
bhavin.vaid@ferring.com
Imperial College London
Hannah MacLachlan
Head of Communications
+44 (0) 207 594 6704
h.maclachlan@imperial.ac.uk
Kate Wighton
Research Media Officer – Medicine
+44 (0) 207 594 2409
k.wighton@imperial.ac.uk
March of Dimes
Michele Kling
Director of Media Relations
+ 1 (914) 997 4613
mkling@marchofdimes.org

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Octapharma Share Promising Preclinical Data for SubQ-8, a Novel Subcutaneous Recombinant FVIII, at WFH 201828.5.2018 10:58Tiedote

Octapharma announced today that pre-clinical data for SubQ-8 were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, UK. SubQ-8, currently under development, is a recombinant FVIII from a human cell line for subcutaneous administration. SubQ-8 is based on Octapharma’s human cell line-derived rFVIII product simoctocog alpha combined with a fragment of the von Willebrand Factor (VWF) protein, and harnesses the protective power of VWF in an innovative approach to facilitate transportation of FVIII into the circulation. Regular intravenous administration of FVIII poses a considerable burden to people with haemophilia A and their families. Alternative routes of administration may help to alleviate some of this burden and improve adherence to prophylaxis therapy. This symposium, entitled ‘Taking FVIII into the future: The development of subcutaneous recombinant human FVIII for the treatment of haemophilia A’, reviewed the challenge

Octapharma present new data on the benefits of Nuwiq® in patients with haemophilia A at the World Federation of Hemophilia 2018 World Congress28.5.2018 10:57Tiedote

Octapharma announced today that new data on the benefits of Nuwiq® in patients with haemophilia A were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, UK. Nuwiq® is a 4th generation human cell line-derived recombinant FVIII (rFVIII) approved for the prevention and treatment of bleeding episodes in patients of all ages with haemophilia A. The symposium, entitled ‘Going further to meet clinical needs: New data with Nuwiq ® ▼ (simoctocog alfa; human-cl rFVIII) from clinical trials and real-world experience’, focused on the challenges within the current haemophilia treatment landscape and opportunities to improve patient care. The symposium, chaired by Craig Kessler, addressed the reality that no two haemophilia A patients are the same. An optimal treatment approach should therefore reflect each individual patient’s profile. Striving towards this goal, two approaches to using pharmacokinetic (PK) data to personalise prophylaxi

Gemalto Announces Collaboration with Qualcomm Technologies to Integrate eSIM Innovation into the Snapdragon Mobile PC Platform28.5.2018 08:00Tiedote

Gemalto announces a new collaboration that will see its advanced mobile connectivity solutions integrated with Qualcomm® Snapdragon™ mobile PC platform, a product by Qualcomm Technologies Inc., a subsidiary of Qualcomm Incorporated. This paves the way for iSIM commercialization on a growing range of Always Connected PCs, laptops and tablets. The effort will support the integration of Gemalto’s eSIM technology and remote subscription management solutions, with the new Secure Processing Unit (SPU) on the Snapdragon mobile PC platform. As a result, this innovation will provide seamless LTE and forthcoming 5G connection, extended battery life, and a foundation for consumer applications such as online payments, transport ticketing and authentication to cloud services. This initiative represents the first time an eSIM will be integrated with processing platforms designed to power Always Connected PCs and similar consumer devices. Providing benefits for industry players: OEMs optimize their b

CES Asia 2018 Announces Innovation Award Honorees27.5.2018 23:00Tiedote

The Consumer Technology Association (CTA) today announced its Innovation Awards Honorees for CES Asia 2018. Now in its second year, the CES Asia Innovation Awards Program celebrates outstanding product design and engineering in brand-new consumer technology products from CES Asia exhibitors. The program recognizes groundbreaking technologies across 20 product categories, including first-time category artificial intelligence (AI) located primarily in SNIEC, Hall N3 at CES Asia 2018. Additional areas of recognition include augmented reality (AR), virtual reality (VR), content, mobile, vehicle tech, smart home, digital health, wearables and more. CES Asia is a global show with exhibiting companies originating from 23 countries, regions and territories. An elite panel of judges with industry expertise in product design and engineering deliberated on the honorees for this prestigious awards program. The honored products excelled in five criteria: engineering, aesthetics, function and user v

FCF: Greenpeace Allegations Unfair and Deceptive26.5.2018 21:02Tiedote

FCF Fishery, Co. President Max Chou today released the following statement regarding recent misleading Greenpeace human rights abuse allegations made against the company: “We realize that as one of the world’s largest marine products integrated supply chain service providers with more than 30 subsidiaries, fishing bases, and shipping agents around the world, we are a prime target for organizations seeking to garner publicity and those not fully aware of the latest development and improvements that are currently taking place in the fishery industry. However, in their efforts to curb egregious human rights abuses, we believe it is unfair and deceptive to lump our company in with those who condone cruelty and neglect of their laborers. “Although we recognize the meaningful work of Greenpeace in exposing and eliminating human trafficking and sustainability abuses, we are equally disappointed that they are implicating FCF in old incidents and cases that have since been in all instances addr

NBC Universal, Havas Group and Endemol Shine Discuss a Future with AI, Blockchain and VR at IBC201825.5.2018 21:20Tiedote

As is fitting for the home of technical invention and innovation, IBC2018 will present a broad range of ambitious and timely elements to engage, inform and inspire content creators and owners from around the world that will visit the RAI, Amsterdam from 13-18 September 2018. The must-attend event includes fresh inspiring conference themes that will focus on innovative new platforms, audience engagement and interaction/immersion, as well as a wide-ranging exhibition that will encompass all the latest technologies from AI and VR to advanced cloud-based workflows. Registration for IBC2018 is now open at: https://ibc.itnint.com/IBC18/Online/RegLogin.aspx “The media landscape is evolving at an unprecedented rate, with new platforms, technologies and even new realities at our disposal that offer greater opportunities for content innovation and audience engagement,” said Michael Crimp, CEO, IBC. “IBC is preparing an outstanding programme of conference sessions, forums and exhibition features

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme